EXPRESSION OF EPIDERMAL GROWTH-FACTOR (EGF), MATRIX METALLOPROTEINASE-9 (MMP-9) AND PROLIFERATING CELL NUCLEAR ANTIGEN (PCNA) IN ESOPHAGEAL CANCER
Expression of human epidermal growth factor (EGF) and matrix metalloproteinase-9 (MMP-9/gelatinase B) was examined immunohistochemically in 62 cases of surgically resected esophageal carcinomas, and the correlation between EGF expression and the proliferative activity of the tumors
was studied by analysing the number of proliferating cell nuclear antigen (PCNA)-positive cells. Expression of EGF and MMP-9 was observed in 16 (38.1%) and 18 (42.9%) of the 42 superficial carcinomas and 8 (40%) and 14 (70%) of the 20 advanced carcinomas, respectively. The differences in the
MMP-9 expression between the superficial carcinomas and the advanced carcinomas was significant (p<0.05). The synchronous expression of EGF and MMP-9 was observed in 15 (24.2%) of 62 carcinomas, i.e. 62.5% of the 24 EGF-positive tumors expressed MMP-9, but there was no statistically significant
correlation between the expression of EGF and MMP-9. The relationships between EGF expression and tumor proliferative activity and prognostic factors were investigated. The PCNA grades were significantly higher in tumors with EGF-positive than those with EGF-negative expression (p<0.05)
and the EGF expression showed a good correlation between the expression of MMP-9 and vascular invasion (p<0.01). The expression of MMP-9 was stronger in the advanced than the superficial carcinomas and there was a good correlation with vascular invasion (p<0.01). In a follow-up study
of 55 patients, those with tumor that expressed MMP-9 or had a high PCNA grade showed a poor prognosis. Taken together, these observations suggest that both EGF and MMP-9 participate in the invasive phenotype in human esophageal carcinoma, but the expression of EGF is not directly related
to the expression of MMP-9. Additional growth factors and cytokines may be involved in regulation of MMP-9 expression in this carcinoma.
No Reference information available - sign in for access.
No Citation information available - sign in for access.
No Supplementary Data.
No Article Media
Document Type: Research Article
UNIV OCCUPAT & ENVIRONM HLTH,SCH MED,DEPT PATHOL,YAHATA KU,KITAKYUSHU,FUKUOKA 807,JAPAN. KURUME UNIV,SCH MED,DEPT SURG,KURUME,FUKUOKA 830,JAPAN. KURUME UNIV,SCH MED,DEPT PATHOL,KURUME,FUKUOKA 830,JAPAN. UNIV KANSAS,MED CTR,DEPT BIOCHEM &
MOLEC BIOL,KANSAS CITY,KS 66160.
UNIV OCCUPAT & ENVIRONM HLTH,SCH MED,DEPT PATHOL,YAHATA KU,KITAKYUSHU,FUKUOKA 807,JAPAN. KURUME UNIV,SCH MED,DEPT SURG,KURUME,FUKUOKA 830,JAPAN. KURUME UNIV,SCH MED,DEPT PATHOL,KURUME,FUKUOKA 830,JAPAN. UNIV KANSAS,MED CTR,DEPT BIOCHEM & MOLEC
BIOL,KANSAS CITY,KS 66160.
April 1, 1995
More about this publication?
The International Journal of Oncology provides an international forum for the publication of the latest, cutting-edge research in the broad area of oncology and cancer treatment. The journal accepts original high quality works and reviews on all aspects of oncology research including carcinogenesis, metastasis, epidemiology, chemotherapy and viral oncology. Through fair and efficient peer review, the journal is dedicated to publishing top tier research in the field, offering authors rapid publication as well as high standards of copy-editing and production. The International Journal of Oncology is published on a monthly basis in both print and early online.
- Editorial Board
- Information for Authors
- Submit a Paper
- Subscribe to this Title
- Information for Advertisers
- Terms & Conditions
- Ingenta Connect is not responsible for the content or availability of external websites